Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. have announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of atopic dermatitis and asthma.
PGI Drug Discovery LLC, the drug discovery arm of Psychogenics Inc., has entered into an exclusive license agreement with F. Hoffmann-La Roche Ltd. to obtain global development, manufacturing and commercialization rights to RO-7117997. Psychogenics intends to evaluate RO-7117997 as a potential treatment for several psychiatric and neurological conditions.
Anaptysbio Inc. has signed an exclusive license agreement for Centessa Pharmaceuticals plc’s blood dendritic cell antigen 2 (BDCA-2) modulator antibody portfolio, including lead asset CBS-004 (to be renamed ANB-101) and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.
Myricx Bio (Myricx Pharma Ltd.) and Wuxi Biologics Co. Ltd. have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on Wuxi Bio's integrated technology platforms.
Beigene Ltd. and Ensem Therapeutics Inc. have announced an agreement for Beigene to acquire an exclusive global license to an IND application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.
South Korean pharmaceutical Voronoi Inc. said that New Jersey-based Pyramid Biosciences Inc. terminated its previous $846 million deal for Voronoi’s solid and breast cancer drug candidate, VRN-08, in a letter dated Oct. 24, 2023.
Mira Pharmaceuticals Inc. has entered into a licensing agreement with Miralogx LLC for exclusive rights in the U.S., Canada and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analogue for depressive disorder treatments.
South Korean pharmaceutical Voronoi Inc. said that New Jersey-based Pyramid Biosciences Inc. terminated its previous $846 million deal for Voronoi’s solid and breast cancer drug candidate, VRN-08, in a letter dated Oct. 24, 2023.
Astrazeneca plc will pay up to $2 billion for Eccogene Co. Ltd.’s oral weight loss candidate, ECC-5004, as big and small pharma players alike work to gain ground in the burgeoning obesity market where Eli Lilly and Co. scored the latest U.S. FDA approval of Zepbound (tirzepatide).
RSS
